CanaQuest is a clinical-stage life sciences company advancing a Phase IIb/III clinical trial with a defined FDA regulatory path and Orphan Drug Designation. Backed by compelling preclinical in vivo efficacy data and guided by former GW Pharma leadership, the company has secured $11M USD in soft commitments from two venture funds, pending bioequivalence studies, which establishes a fast-to-market trajectory and positions the company for a strategic exit of $500M-$1.5B.